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Abstract
Background: There is a continuing need to develop molecular diagnostic tools which complement
histopathologic examination to increase the accuracy of cancer diagnosis. DNA microarrays
provide a means for measuring gene expression signatures which can then be used as components
of genomic-based diagnostic tests to determine the presence of cancer.
Results: In this study, we collect and integrate ~ 1500 microarray gene expression profiles from
26 published cancer data sets across 21 major human cancer types. We then apply a statistical
method, referred to as the Top-Scoring Pair of Groups (TSPG) classifier, and a repeated random
sampling strategy to the integrated training data sets and identify a common cancer signature
consisting of 46 genes. These 46 genes are naturally divided into two distinct groups; those in one
group are typically expressed less than those in the other group for cancer tissues. Given a new
expression profile, the classifier discriminates cancer from normal tissues by ranking the expression
values of the 46 genes in the cancer signature and comparing the average ranks of the two groups.
This signature is then validated by applying this decision rule to independent test data.
Conclusion: By combining the TSPG method and repeated random sampling, a robust common
cancer signature has been identified from large-scale microarray data integration. Upon further
validation, this signature may be useful as a robust and objective diagnostic test for cancer.
Background
During the past century, the presence of cancer in tissues
has been diagnosed on the basis of histopathology [1].
The major limitation of this approach is that it cannot
achieve high accuracy of prediction in clinical practice.
Therefore, there has been a persistent need to identify
robust cancer signatures which could complement con-
ventional histopathologic evaluation to increase the accu-
racy of cancer detection [2]. More recently, DNA
microarrays have been developed as a means to simulta-
neously measure the transcript abundance (gene expres-
sion level) of mRNA for thousands of genes. This
technology provides a potentially powerful tool for iden-
tifying molecular signatures capable of accurately detect-
ing the presence of cancer.
Many studies have used DNA microarrays to identify can-
cer type-specific gene expression signatures which can dis-
criminate certain types of cancer from normal tissues [3-
15]. The diversity of these signatures makes it difficult to
distinguish the genes that play a crucial role in oncogenic
processes from those that are spuriously differentially
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expressed and therefore irrelevant to the oncogenic proc-
esses. Since all cancer cells share two common character-
istics, uncontrollable growth and local tissue invasion or
metastasis, it is of high importance to identify a universal
cancer type-independent signature to better understand
cancer pathogenesis and ultimately to improve therapeu-
tics. After such a signature is identified, it could be used as
a component of genomic-based clinical diagnostic tools
for cancer patients to determine the presence of cancer
cells in tissues.
Recently, several studies used meta-analysis methods to
identify genes differentially expressed across multiple can-
cer types [16-18]. In the study of Rhodes et al. [17], 21
published cancer microarray data sets, spanning 12 dis-
tinct cancer types, were collected and analyzed in an effort
to identify a cancer type-independent transcriptional sig-
nature of neoplastic transformation. A statistical meta-
analysis method, termed comparative meta-profiling, was
proposed to compare and assess the intersection of many
cancer type-dependent signatures, the goal being to iden-
tify a common cancer meta-signature. The comparative
meta-profiling method works as follows. First, an overex-
pression direction (e.g. cancer > normal) and significant
threshold are set to define differential gene expression sig-
natures from a set of cancer versus normal studies (one
signature per study). Next, genes are sorted by the number
of signatures in which they are present. Finally, a meta-sig-
nature is defined as those genes appearing in a given
number of signatures [17], where the cutoff is determined
by a random simulation. Rhodes et al used this method to
identify a set of 67 genes that are universally activated in
most cancer types relative to corresponding normal tis-
sues.
One limitation of meta-analysis of microarray data is that
small sample sizes typical of individual studies, coupled
with variation due to differences in study protocols, inev-
itably degrades the results of meta-analysis. An additional
and major limitation of the comparative meta-profiling
method is that those genes which are common to the var-
ious array platforms used in these studies are highly over-
represented in the identified meta-signature. This way of
defining a meta-signature by gene enrichment in signa-
tures implies that many potentially informative genes
which are not common to the various array platforms
used in these studies may be overlooked due to the intrin-
sic properties of this method. As a specific example, the
relationship between the numbers of total genes on two
major Affymetrix microarray platforms used in the study
of Rhodes et al. and the corresponding numbers of genes
included in the reported common cancer meta-signature
is shown in the Venn diagram of Figure 1. Among the 67
meta-signature genes, 59 genes are on one or both of these
two microarray platforms and the other eight genes come
from other microarray platforms. Almost all of the 59
meta-signature genes come from the set of 5127 genes
which are common across the two microarray platforms
employed in this study.
In our previous work, we proposed a novel, simple
method, referred to as the top-scoring pair (TSP) classifier,
to integrate inter-study microarray data and validated the
method on prostate cancer data [14]. It has also been
applied recently to differentiating between gastrointesti-
nal stromal tumors and leiomyosarcomas [19]. The TSP
method is based only on the ranks of the expression val-
ues within a profile and hence there is no need to perform
data normalization and transformation before data inte-
gration because rankings are invariant to nearly all types
of preprocessing. Further, the TSP method identifies only
a pair of genes as a gene signature and the decision rule is
based simply on comparing their expression values. This
approach to data integration was validated on prostate
cancer data [14], resulting in a powerful two-gene diag-
nostic classifier. Here, we extend this method to predict
distant metastases in breast cancer, and attempt to over-
come the limitations of previous study-specific methods
and meta-analyses.
Here, we present a generalization of this method, termed
top-scoring pair of groups (TSPG), which preserves the
basic properties of the TSP classifier, namely invariance to
normalization and comparison-based rules, but incorpo-
rates more genes into the decision-making. We apply this
generalization to identify a cancer type-independent sig-
Common genes overrepresented in the meta-signature Figure 1
Common genes overrepresented in the meta-signa-
ture. The figure shows the relationship between the num-
bers of genes on two microarray platforms, HuGeneFL and 
HG-U95A, and the corresponding numbers of genes in the 
meta-signature of neoplastic transformation [17]. There are 
5127 genes common to both platforms, 238 only on HuGen-
eFL and 3592 only on HG-U95A. The numbers without 
parentheses are the corresponding numbers of genes in the 
meta-signature.BMC Bioinformatics 2007, 8:275 http://www.biomedcentral.com/1471-2105/8/275
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nature by integrating microarray data from different can-
cer studies across almost all major human cancer types.
This overcomes the limitations of previous meta-analyses
by integrating large-scale microarray data generated using
the same microarray platform, resulting in one signature
per platform (rather than per study) and effectively
increasing sample size. Integrating microarray data from
the same platform can guarantee that all the genes on the
platform will be included in the analysis, therefore avoid-
ing losing any potential signature genes. Moreover, unlike
the approach in [17], which requires cross-validation for
decision-making, and hence an ensemble of new samples
for testing the predictive power of the common signature,
the TSPG method provides a classifier in the standard
sense of a prediction rule which can be applied to label a
single new sample.
By combining the TSPG method and a repeated random
sampling strategy, a common cancer signature, which
consists of 46 distinct genes, is identified from the inte-
grated microarray data. The TSPG classifier, which dis-
criminates cancer from normal samples, is built from the
signature and validated on both the training data and
independent cancer microarray data. Upon further valida-
tion on large-scale independent data, the signature may
be used to develop a novel cancer diagnostic tool and pro-
vide new insights regarding the mechanism of cancer.
Results
Data collection
Microarray data sets were obtained from public gene
expression data repositories, including Gene Expression
Omnibus [20], Oncomine [21] and supporting web sites
identified from the published literature. In particular, we
focused on analysis of human cancer gene expression data
obtained using the Affymetrix HuGeneFL, HG-U95A and
HG-U133A microarray platforms. Of these collected data,
26 individual data sets generated from HuGeneFL arrays
(Table 1) and HG-U95A arrays (Table 2) were used as
training data and six individual data sets from HG-U133A
arrays (Table 3) were used as independent test data. In
total, 1593 microarray experiments from 32 independent
Table 1: Microarray data from Affymetrix HuGeneFL arrays
Study Class1 Size Class2 Size
Beer_Lung [25] Normal Lung 10 Lung Adenoarcinoma 86
Dyrskjot_Bladder [26] Normal Bladder 4 Bladder Cancer 40
Hippo_Gastric [27] Normal Gastric Tissues 8 Gastric Cancer 22
Hsiao_Normal [28] Normal Tisues 59
Lancaster_Ovarian [29] Normal Ovary 3 Ovarian Adenocarcinoma 31
Logsdon_Pancreas [30] Normal Pancreas 5 Pancreatic 
Adenocarcinoma
10
Pomeroy_Brain [31] Normal Cerebellum 4 Atypical Teratoid/Rhabdoid 
Tumors
10
Primitive neuroectodermal 
Tumors
8
Malignant Gliomas 10
Medulloblastoma 10
Quade_Myometrium [32] Normal Myometrium 4 Leiomyosarcoma 14
Ramaswamy_Multi [33] Normal Prostate 9 Prostate Cancer 10
Normal Uterus 6 Uterine Cancer 10
Normal Whole brain 8 Glioblastoma/
Medulloblastoma
20
Normal Breast 5 Breast Adenocarcinoma 11
Normal Lung 7 Lung Adenoarcinoma 11
Nromal Colon 11 Colorectal 11
Normal Germinal Center 6 Lymphoma 22
Normal Bladder 7 Bladder Cancer 11
Melanoma 10
Peripheral Blood 5 Leukemia 30
Normal Kidney 12 Renal Cell Carcinoma 11
Normal Pancreas 10 Pancreatic 
Adenocarcinoma
11
Normal Ovary 4 Ovarian Carcinoma 11
Mesothelioma 11
Rickman_Brain [34] Normal Temporal Lobe 6 Glioma 45
Welsh_Ovarian [35] Normal Ovary 4 Ovarian Carcinoma 22
Zhan_Myeloma [36] Normal Plasma Cell- Bone 
Marrow
30 Multiple Myeloma 74
Total Normal Tissues 227 Cancer Tissues 572BMC Bioinformatics 2007, 8:275 http://www.biomedcentral.com/1471-2105/8/275
Page 4 of 13
(page number not for citation purposes)
Table 2: Microarray data from Affymetrix HG-U95A arrays
Study Class1 Size Class2 Size
Bhattacharjee_Lung [37] Normal Lung 17 Small Cell Lung Carcinoma 6
Lung Carcinoid 20
Squamous Cell Lung 
Carcinoma
21
Cromer_Head-Neck [38] Normal Uvula 4 Head-Neck Squamous Cell 
Carcinoma
34
Dehan_Lung [39] Normal Lung 9 Lung Adenocarcinoma 7
Lung Squamous Cell 
Carcinoma
17
Lung Adenosquamous 1
Frierson_Salivary [40] Normal Salivary Gland 6 Salivary Carcinoma 16
Giordano_Adrenal [41] Normal Adrenal Cortex 3 Adrenocortical Carcinoma 11
Gutmann_Brain [42] Normal White Matter 3 Pilocytic Astrocytoma 8
Huang_Thyroid [43] Normal Thyroid 8 Thyroid Carcinoma 8
Shai_Brain [44] White Matter 7 Glioblastoma Multiforme 35
Stearman_Lung [45] Normal Lung 19 Lung Tumor 20
Su_Multi [46] Normal Tissues 63 Tumor Tissues 18
Su_Tumors [5] Prostate Cancer 24
Bladder/Ureter 8
Breast 21
Colorectal 21
Gastroesophagus 11
Kidney 10
Liver 6
Ovary 23
Pancreas 6
Lung Adenocarcinoma 12
Lung Squamous Cell 
Carcinoma
12
Welle_Normal [47] Normal Muscle 12
Yanai_Normal [48] Normal Tissues 24
Yu_Prostate [49] Normal Prostae 16 Primary Prosate 
Carcinoma
35
Total Normal Tissues 191 Cancer Tissues 411
Table 3: Microarray data from Affymetrix HG-U133A arrays
Study Class1 Size Class2 Size
Gordon_Lung [50] Normal Lung 4 Malignant Pleural 
Mesothelioma
40
Normal Pleura 5
Hoffman_Myometrium [51] Normal Myometrium 5 Uterine Leiomyomas 5
Lenburg_Kidney [52] Normal Kidney Tissue 5 Renal Cell Carcinoma 12
Talantov_Skin [53] Normal Skin 7 Melanoma 45
Wachi_Lung [54] Normal Lung 5 Squamous Lung Cancer 5
Yoon_Soft_Tissue [55] Normal Soft Tissue 15 Soft Tissue Sarcoma 39
Total Normal Tissues 46 Cancer Tissues 146BMC Bioinformatics 2007, 8:275 http://www.biomedcentral.com/1471-2105/8/275
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studies across almost all human cancer types were used in
this analysis. Studies are named using the same conven-
tion as in [17]: FirstAuthor_Tissue (e.g. Beer_Lung).
Common cancer signature
We directly merge 12 (respectively, 14) cancer/normal
microarray data sets generated from Affymetrix HuGeneFL
(respectively, HG-U95A) (Table 1 and 2), using the com-
mon 7069 (respectively, 12532) probe sets among all
these data sets to form an integrated training data set with
799 (respectively, 602) samples. These data sets span 21
tissue types including lung, breast, bladder, ovarian, pan-
creas, brain, prostate, uterus, colon, blood, kidney, uvula,
salivary gland, thyroid gland, liver, skin, gastric tissue,
myometrium, bone marrow, adrenal cortex and gastro-
esophagus. For each of the two integrated data sets, we
randomly select S% = 90% of the total samples from the
integrated data set and then apply the TSPG algorithm to
the selected data to construct two groups, G1 and G2, of
genes. After the experiment is repeated 1000 times, the
appearance frequency for each gene which is present in
any of the 1000 G1's (respectively, G2's) is calculated. For
the default frequency threshold F = 80%, the appearance
frequency of 24 genes (13 in G1 and 11 in G2) from the
HuGeneFL integrated data set and 25 genes (12 in G1 and
13 in G2) from the HG-U95A integrated data set exceeds F
(Table 4). There are three genes (CLEC3B, COX7A1 and
KIAA0101) which are selected from both integrated data
sets. Therefore, a common cancer signature, which con-
sists of the 46 genes (24 in G1 and 22 in G2) obtained from
the two integrated data sets, is identified from the inte-
grated microarray data. For F = 90% and 70% the com-
mon cancer signatures consist of slightly different genes.
(For F = 90%, 39 out of the above 46 genes appear and for
F = 70% 10 more genes are added to the 46 genes.) For the
rest of this paper, we will focus on the 46-gene common
cancer signature corresponding to F = 80%.
Validation of the common cancer signature on the training 
data
To validate the reliability and robustness of the common
cancer signature, the TSPG classifier, which predicts can-
cer vs. normal status, is built based on all the signature
genes, with 24 genes in G1 and 22 genes in G2 as indicated
above. The classification rule for the TSPG classifier is that
if the average relative rank of the genes in G1 is less than
Table 4: Common cancer signature genes
Microarray Platform G1 G2
Gene Symbol Probe Set ID Gene Symbol Probe Set ID
HuGeneFL BOP1 D50914_at COX7A1 M83186_at
PON2 L48513_at CXCL12 U19495_s_at
NME1* X17620_at ALDH1A1 M31994_at
CKS2* X54942_at SELP M25322_at
CCT3 X74801_at CD36 Z32765_at
KIAA0101* D14657_at CSRP1 M76378_at
FOXM1 U74612_at C9orf61 L27479_at
MAP3K11 L32976_at MYH11 AF001548_rna1_at
RAB13 X75593_at LTC4S U50136_rna1_at
ARPC1B AF006084_at DEFA4 X65977_at
HMGA1 L17131_rna1_at CLEC3B X64559_at
TYMS D00596_at
DNMT1 X63692_at
HG-U95A SOX4* 33131_at TEK 1596_g_at
C7orf24 41696_at FXYD1 32109_at
POSTN 1451_s_at ABCA8 35717_at
BAZ1B 32261_at CLEC3B 36569_at
KIAA0101* 38116_at CBX7 36894_at
RECQL 34684_at TNXA///TNXB 38508_s_at
FAT 40454_at SH3BP5 38968_at
SIPA1L3 37831_at CA4 40739_at
MARCKSL1 36174_at FBXO9 38990_at
CKAP4 32529_at COX7A1 39031_at
KIF14 34563_at GABARAPL1 35785_at
SUB1 36171_at ADH1B 35730_at
PTGDS 216_at
* These genes were also identified as common cancer signature genes in Rhode et al. [17].BMC Bioinformatics 2007, 8:275 http://www.biomedcentral.com/1471-2105/8/275
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that of the genes in G2, a test sample is classified as nor-
mal; otherwise it is classified as cancer. The expression val-
ues of the 46 signature genes are illustrated in Figure 2
using some of the training data, including
Stearman_Lung, Frierson_Salivary, Giordano_Adrenal
and Gutmann_Brain data sets. Distinct patterns of expres-
sion values of the genes in G1 and G2 can be observed for
normal and cancer samples. The classifier is then used to
assess the prediction accuracy of the signature on the
training data sets spanning a wide range of cancer types.
For the 26 individual data sets which have been integrated
and used to identify the signature, the classification accu-
racy and the p-values of the Fisher's exact test are shown in
Table 5. The classifier achieves high accuracy (> 85%) on
19 of 26 data sets and the overall accuracy is about 86%.
From the p-values of the Fisher's exact test, we learn that
the classification is significant (p-value < 0.03) on 18 of 22
data sets. There is no p-value available for four data sets
which only have samples from one class. The classifier is
both significant (p-value < 0.03) and accurate (> 85%) on
14 of 22 data sets. The results suggest that we have identi-
fied a common cancer signature for most, if not all,
human cancer types.
Validation of the common cancer signature on 
independent test data
To further validate the generality and robustness of the
common cancer signature, the TSPG classifier built based
on the signature is tested on six independent test data sets
generated from a different generation of Affymetrix micro-
array platforms, HG-U133A (Table 3). The six independ-
ent data sets represent six different human cancer types,
Common cancer signature which can discriminate cancer from normal samples Figure 2
Common cancer signature which can discriminate cancer from normal samples. Some of the training data 
(Stearman_Lung, Frierson_Salivary, Giordano_Adrenal and Gutmann_Brain) is used to illustrate the gene expression values of 
the signature genes in the figure. The heatmap is generated by the matrix2png software [24]. For each data set, the expression 
value for each gene is normalized across the samples to zero mean and one standard deviation (SD) for visualization purposes. 
Genes with expression levels greater than the mean are colored in red and those below the mean are colored in green. The 
scale indicates the number of SDs above or below the mean.BMC Bioinformatics 2007, 8:275 http://www.biomedcentral.com/1471-2105/8/275
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one of which is not represented in the training data sets
(Yoon_Soft_Tissue). The classification accuracy and statis-
tical significance (i.e. p-value of the Fisher's exact test) of
the common cancer signature are listed in Table 6. The sig-
nature significantly (p-value < 0.005) discriminates cancer
from normal samples with very high accuracy (> 95%) on
four of the six data sets, including the new cancer type data
set. On the other two data sets, the signature achieves
much higher accuracy (> 75%) than that of coin-flipping
but only marginally significant (p-value = 0.083 and
0.107). The independent test results have validated that
the signature is common to a wide range of cancer types
and may be used to detect the presence of cancer cells in
tissues.
Comparison with the Rhodes signature
We compare our common cancer signature to the one for
meta-signature of neoplastic transformation reported in
Table 5: Class prediction of the common signature on training data
Microarray Platform Study Number of Normal 
Samples
Number of Cancer 
Samples
Accuracy (%) P-value
HuGeneFL Beer_Lung 10 86 95.8 8.87E-11
Dyrskjot_Bladder 4 40 95.5 1.18E-03
Hippo_Gastric 8 22 76.7 2.67E-01
Hsiao_Normal 59 0 91.5 N/A*
Lancaster_Ovarian 3 31 91.2 1.00
Logsdon_Pancreas 5 10 100 3.33E-04
Pomeroy_Brain 4 38 97.6 3.48E-04
Quade_Myometrium 4 14 77.8 2.29E-02
Ramaswamy_Multi 90 190 77.9 1.28E-20
Rickman_Brain 6 45 94.1 2.87E-04
Welsh_Ovarian 4 22 100 6.69E-05
Zhan_Myeloma 30 74 72.1 2.88E-01
Overall 
(HuGeneFL)
227 572 85.0 6.70E-68
HG-U95A Bhattacharjee_Lung 17 47 90.6 6.34E-10
Cromer_Head-Neck 4 34 97.4 4.74E-04
Dehan_Lung 9 25 85.3 3.82E-05
Frierson_Salivary 6 16 95.5 9.38E-05
Giordano_Adrenal 3 11 92.9 1.10E-02
Gutmann_Brain 3 8 100 6.06E-03
Huang_Thyroid 8 8 75 5.59E-02
Shai_Brain 7 35 85.7 6.36E-05
Stearman_Lung 19 20 89.7 1.28E-07
Su_Multi 63 18 81.5 1.15E-05
Su_Tumors 0 154 93.5 N/A
Welle_Normal 12 0 100 N/A
Yanai_Normal 24 0 91.7 N/A
Yu_Prostate 16 35 54.9 1.83E-02
Overall (HG-
U95A)
191 411 87.0 3.65E-77
* For the data sets with samples from only one class, no p-value is available.
Table 6: Validation of the common signature on independent HG-U133A data
Study Number of Normal 
Samples
Number of Cancer 
Samples
Accuracy (%) P-value
Gordon_Lung 9 40 95.9 1.75E-07
Hoffman_Myometrium 5 5 80.0 8.33E-02
Lenburg_Kidney 5 12 76.5 1.07E-01
Talantov_Skin 7 45 98.1 3.44E-07
Wachi_Lung 5 5 100 3.97E-03
Yoon_Soft_Tissue 15 39 96.3 6.76E-11
Overall 46 146 94.3 9.74E-30BMC Bioinformatics 2007, 8:275 http://www.biomedcentral.com/1471-2105/8/275
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[17]. It is not surprising that there is a small overlap
between the two signatures with four common genes (see
Table 4). On the one hand, this implies that both studies
have identified some molecular features common to all
cancer types. On the other hand, the difference between
the two signatures may result from the two major differ-
ences between the two methods. First, the comparative
meta-profiling method overlooks a large number of
potential signature genes due to its intrinsic properties
whereas our method includes all possible genes in the
analysis. Second, the analysis in [17] focuses on differen-
tially expressed genes; more specifically, it chooses genes
which are over-expressed in one direction (cancer > nor-
mal). In contrast, our selection criterion is not based on
differential expression, but rather on finding pairs of
genes whose expression values typically invert from can-
cer to normal tissues. One consequence is that our signa-
ture includes genes over-expressed in both directions, as
illustrated in Figure 2, as well as genes which are not dif-
ferentially expressed.
We then compare the classification performance of the
two signatures on the same independent test data. Results
are reported in Table 7. In this way the two signatures and
corresponding cancer prediction rules are evaluated on
completely independent data not involved in learning
either signature. Significantly, the approach in Rhodes
[17] does not provide a well-defined classifier correspond-
ing to the signature; important aspects of the classifier
must be learned on the test data, producing an upwardly-
biased estimate of classification accuracy. (A more com-
plete explanation appears in "Methods.") Nonetheless,
the TSPG classifier based on our common signature out-
performs the classifier based on the Rhode signature [17]
on three of the six independent test data sets and achieves
the same accuracy on the other three data sets. Unlike the
Rhodes classifier, the TSPG classifier is completely deter-
mined by the signature itself and was applied sample-by-
sample to the test data; no learning on the test data was
involved.
Discussion
The advent of DNA microarray has had a tremendous
impact on cancer research. This technology provides a
novel molecular tool, complementary to histopathologic
examination, to assess the presence of cancer cells in
patient tissues. The rapid accumulation of cancer microar-
ray data makes it possible to integrate a large amount of
microarray gene expression data across a wide range of
cancer types to identify a universal cancer signature to
detect cancer cells, regardless of the tissue from which the
cancer is derived. In this study, by integrating microarray
data and applying the TSPG method combined with
repeated random sampling, we have identified a robust
cancer gene expression signature common to almost all
major human cancer types. The discriminative power of
the signature has been validated on both data sets
involved in identifying the signature and independent test
data sets. The TSPG classifier built from the signature,
which simply compares the average relative ranks of two
groups of genes, achieves high accuracy on most of the
training and test data sets with statistical significance.
Although the signature has the potential to be developed
as a robust and objective clinical diagnostic test for cancer,
larger number of samples will be required to further refine
and validate it.
An intriguing advantage of inter-study cancer microarray
data integration is that it increases the statistical power to
capture essential, cancer type-independent gene expres-
sion features, which might be masked by specific features
of individual cancer types and small sample sizes of indi-
vidual data sets. In this sense, the signature is reliable and
robust to variations in individual cancer data sets. The
universal cancer signature described here may play a cru-
cial role in oncogenic processes and be used to improve
our understanding of cancer pathogenesis and ultimately
design improved anticancer treatments. It also suggests
the possible existence of therapeutic targets common to
different cancer types.
Table 7: Comparison with the Rhodes signature on the same independent data
Study Rhodes Signature Our Signature
Accuracy (%) P-value Accuracy (%) P-value
Gordon_Lung 91.8 3.48E-07 95.9 1.75E-07
Hoffman_Myometrium 80.02 . 0 6 E - 0 18 0 . 08 . 3 3 E - 0 2
Lenburg_Kidney 76.5 1.01E-01 76.5 1.07E-01
Talantov_Skin 94.2 8.97E-07 98.1 3.44E-07
Wachi_Lung 100 3.97E-03 100 3.97E-03
Yoon_Soft_Tissue 85.2 5.67E-8 96.3 6.76E-11
Overall 89.1 9.28E-26 94.3 9.74E-30BMC Bioinformatics 2007, 8:275 http://www.biomedcentral.com/1471-2105/8/275
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We have observed that the signature seems to perform bet-
ter for certain tissue types, such as lung, skin, and soft tis-
sue cancer. There are many possible reasons to cause the
different performance of the signature on different cancer
types. These reasons may include differences in sample
composition and preparation, experimental protocols,
RNA quality, proportion of cancer cells in a tissue, and
microarray quality. In addition, some cancer types might
be easier to detect than other cancer types.
It is not surprising that many of the signature genes
(BOP1, KIAA0101, CCT3, ARPC1B, CKAP4, ALDH1A1,
CD36, CLEC3B, TEK, CBX7) have been reported to be
associated with specific types of cancer in the literature
and some other genes (NME1, TYMS, POSTN, FOXM1,
HMGA1, DNMT1, KIF14, CXCL12, SELP) have been pre-
viously found to be associated with a variety of distinct
human cancer types. As defined by Gene Ontology Con-
sortium, the common signature genes are involved in cell
cycle (MAP3K11, NME1, CKS2, MYH11), regulation of
transcription (BAZ1B, SOX4, FOXM1, SUB1, CBX7,
DNMT1, HMGA1, RAB13), DNA metabolism (RECQL,
CBX7, DNMT1, TYMS, HMGA1), cellular biosynthesis
(NME1, PTGDS, KIF14, TYMS, LTC4S), cellular protein
metabolism (MAP3K11, TEK, KIF14, FBXO9, HMGA1,
CCT3) and other important biological processes, such as
cell organization and cell adhesion. These findings are
consistent with the fact that all cancer types share the com-
mon features of uncontrollable cell growth and local tis-
sue invasion, and therefore the genes that are essential to
these cellular processes are possible signature genes
among almost all cancer types.
One limitation of our proposed method for microarray
data integration is that it can only directly integrate micro-
array data generated from the same standard microarray
platforms. Even with this limitation, we still obtain a large
number of samples (> 500) on each of the two microarray
platforms used in this study. With the rapid increase of
available microarray data and the standardization of
microarray technologies, the mass of microarray data gen-
erated from the same platforms will continue to grow,
which will make our method become increasingly useful.
It is quite interesting that a similar study on common can-
cer biomarkers was published very recently [22]. The
uniqueness of the study is that the researchers have gener-
ated microarray data across various cancer types using the
same spotted cDNA microarray, and therefore no data
integration is needed. By applying a gene pairing method
to a training set with 201 samples of various normal and
cancer tissues, a subset of 14 genes identified as common
cancer biomarkers with high predictive power (87%) in
segregating cancer from normal samples. Two of the 14
genes, PON2 and SOX4, have also been identified in our
common cancer signature. The major limitation of the
study is that the cancer samples are dominated by only a
few cancer types (colon, melanoma, ovarian and esopha-
geal cancers). Therefore, the biomarkers identified in the
study may not really be common to a broad range of can-
cer types. In our study, motivated by the work of Rhodes
et al., we collected a broader range of microarray gene
expression data for about 20 cancer types and each of
them is reasonably represented in the training data sets.
The signature identified in our study has been validated
on independent data sets of various cancer types, includ-
ing one cancer type which is not represented in the train-
ing data sets. 
Finally, we have also compared our classifier with the
method in Rhodes et al. on the same test sets; in this way
the two signatures and corresponding cancer prediction
rules are evaluated on completely independent data not
involved in learning either signature. In classifying a test
sample, the Rhodes classifier must use all the other sam-
ples in the same test set to compute class averages; hence
cross-validation is necessary. In contrast, our classifier
operates in the conventional way, classifying each sample
independently of all others. Despite this source of bias in
the Rhodes classifier, our method still achieves higher
overall accuracy.
Conclusion
In conclusion, by combining large-scale microarray data,
a robust common cancer signature has been identified.
Upon more large-scale validation, it could be developed
as a component of genomic-based clinical diagnostic
tools for cancer patients. Further studies of the signature
might also improve our understanding of cancer and
identify new drug targets.
Methods
TSPG classifier
Recently, our group has developed a family of statistical
molecular classification methods, referred to as the TSP
and the k-TSP classifiers [13,15], and applied the TSP clas-
sifier to microarray data integration [14]. These methods
only use the ranks of gene expression values within each
profile and achieve impressive results in both molecular
classification and microarray data integration [13-15]. An
important feature of rank-based methods is that they are
invariant to monotonic transformations of the expression
data within an array, such as those used in most data nor-
malization methods. This property makes these methods
useful for combining inter-study microarray data without
the need to perform data normalization and transforma-
tion. Here, we present a similar but more robust method,
termed the TSPG classifier, in order to identify a gene
expression signature common to a wide range of cancer
types by integrating large-scale cancer microarray data.BMC Bioinformatics 2007, 8:275 http://www.biomedcentral.com/1471-2105/8/275
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The development of the TSPG method is motivated by fol-
lowing considerations. It is known that many genes are
involved in the oncogenic processes; therefore, in order to
better understand cancer pathogenesis, we need to iden-
tify a common cancer signature which consists of more
than just a few genes. The TSP method previously used
only identifies a pair of signature genes, say i and j, which
obviously cannot constitute an effective common cancer
signature. The basic idea it to replace i and j by two groups
G1 and G2 of genes, but preserve the property of basing
prediction on expression comparisons as well as the scor-
ing mechanism. Instead of simply comparing the ranks of
the expression values of genes i and j, we rank all the genes
in the two groups G1 and G2 and compare the average
ranks G1 and G2. When each group consists of a single
gene, the TSPG method reduces to TSP.
Another motivation for developing the TSPG method is
related to the observation that, in some cases, one gene
may pair with different genes to form a top-scoring pair
when the training data is perturbed by adding or deleting
a few samples. This may imply that a gene consistently
appearing in top-scoring pairs may be closely correlated to
cancer whereas the other genes occasionally paired with it
might be irrelevant to cancer. We want to keep those genes
which may play a crucial role in oncogenic processes in
the common cancer signature and eliminate those genes
which may be irrelevant to cancer. When combined with
repeated random sampling, the TSPG method provides
the flexibility to keep one gene of a TSP in a signature
while excluding the other one from it.
The TSPG classifier is defined as follows. Assume the train-
ing microarray data are represented by a P × N matrix X =
[Xpn], p = 1, 2, ..., P and n = 1, 2, ..., N, where P is the
number of genes in each profile and N is the number of
samples (i.e. profiles). Each column n represents a gene
expression profile of P genes with a class label Yn = 1 (nor-
mal) or 2 (cancer) for the two-class problem (normal vs.
cancer) in this study. Among the N samples, there are N1
(respectively, N2) samples labeled as class 1 (respectively,
class 2) with N = N1 + N2. For each pair of genes (i, j),
where i, j = 1, 2, ..., P, i ≠ j, we define a score as
∆ij = |P(Xi <Xj | Y = 1) - P(Xi <Xj | Y = 2)| (1)
and estimate the score based on the training set X by
where
For those pairs that achieve an identical score, we use a
secondary score, called the rank-score, to break the tie
[14,15]. The rank-score takes into account the extent to
which a gene pair inverts from one class to the other. For
each pair (i, j), the rank-score, denoted by δij, is defined as
Here Rin is the rank of the expression value of gene i within
the n-th profile in ascending order.
The TSPG algorithm constructs two disjoint groups (or
sets) of genes, G1 and G2, with |G1|+|G2| <<P, where |Gl|
denotes the number of genes in group Gl, l = 1,2. The clas-
sifier makes a prediction based on the average relative
ranks of the genes in the two groups. The decision rule of
the classifier is based on all the genes in G1 and G2. Let Wi,
i ∈ G = G1 ∪ G2, be the relative ranks of the genes within
G in ascending order and let E denote the event that the
average relative rank of the genes in G1 is less than that of
the genes in G2, that is,
The decision rule of the TSPG classifier is then very simple:
Given a test sample X = [X1, ..., XP], if we observe that event
E, then the classifier selects class 1; otherwise, it selects
class 2. Notice the decision rule is based only on the rela-
tive ordering among the transcript abundances for the
genes in G.
Ideally, the two groups of genes in the TSPG algorithm
would be determined by maximizing a score analogous to
(1), but with the event {Xi <Xj} replaced by E. Needless to
say, this is an intractable optimization problem as it
would involve optimizing over all pairs of subsets of
genes. Instead, we do something sub-optimal but simple:
we construct the groups directly from the k top-scoring
pairs of genes, where we fix k = 20; no other values of k
were attempted, although performance could likely be
improved by choosing k based on cross-validation. Specif-
ically, we first form a list of gene pairs, sorted from the
largest to the smallest according to their scores ∆ij, with
ties (if there are any) broken by using the rank-score δij.
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Next, the k disjoint top-scoring pairs are selected from the
list. (In the k-TSP classifier [15], a decision is made by sim-
ple voting among the k  top-scoring pairs.) Finally, we
assign each of these selected genes to either G1 or G2. For
each pair (i,  j) among the k  selected pairs, if
, then gene i is assigned to G1and
gene j is assigned to G2; otherwise, gene j is assigned to G1
and gene i  is assigned to G2. In this way, the genes
assigned to G1  tend to be expressed less than those
assigned to G2.
Data integration
Since rank is invariant to within-array monotonic data
transformations, by applying the rank-based TSPG
method, which performs on-chip comparisons within
each microarray, no data normalization and transforma-
tions are required before integration. For microarray data
generated from the same platform, we directly merge indi-
vidual data sets using the common probe sets across all
the data sets to form an integrated data set of increased
sample size. To merge data from different generations of
the same array technology, we first select the common
probe sets across the platforms and then merge data using
the common probe sets. In that case, a large number of
genes, which are not in the common set and may include
potential signature genes, will be excluded from analysis.
In this study, we focus on integrating microarray data gen-
erated using same platform to avoid losing any potential
signature genes. Specifically, we integrate microarray data
generated from both Affymetrix HuGeneFL and HG-U95A
microarray platforms to form two corresponding inte-
grated data sets with large (> 500) sample sizes. These two
integrated data sets are used as training data sets to iden-
tify a common cancer signature.
Repeated random sampling and signature gene selection
A recent study by Michiels et al. has shown that molecular
signatures strongly depend on the selection of patient
samples in the training sets and they advocate the use of
repeated random sampling for signature validation [23].
Motivated by their work, we combine the TSPG algorithm
with a repeated random sampling strategy in order to
obtain a more robust and reliable common cancer signa-
ture. We randomly select S% of the total samples from an
integrated training set, with S chosen close to 100, specif-
ically S = 90, in order to reasonably represent the original
training samples. We then apply the TSPG algorithm to
the selected subset of the original training set to construct
two groups, G1 and G2, of genes, with a predefined value
of k, the number of genes in each group. After repeating
this experiment a large number of times, we calculate the
appearance frequency of each gene in Gl, l = 1, 2. A fre-
quency threshold F (default, F = 80%) is set to select those
genes whose appearance frequency exceeds the threshold
in Gl, l = 1, 2. The final common cancer signature consists
of all the genes picked from G1 and G2 for each of the two
integrated training data sets, HuGeneFL and HG-U95A.
Class prediction
To assess the classification accuracy of the common cancer
signature, we build a TSPG classifier based on all the sig-
nature genes. The signature genes picked up from G1's
(respectively, G2's) of the two integrated training sets by
repeated random sampling form the group G1 (respec-
tively, G2) of the TSPG classifier. The classifier votes for
class 1 (i.e. normal) if the average relative rank of the
genes in G1 is less than that of the genes in G2; otherwise,
it votes for class 2 (i.e. cancer). We not only use the classi-
fier to predict samples from data sets involved in identify-
ing the signature, but also validate it on independent data
sets. A Fisher's exact test is used to assess the significance
of the classification accuracy. The classification accuracy,
as well as its statistical significance, is reported for all the
individual data sets, training and test.
In Table 7 we compared the TSPG classifier with the one
described in Rhodes [17], which requires the existence of
an ensemble of samples to learn class averages for each
gene in the signature. A new sample is then classified
according to the class (cancer or normal) which receives
the most votes in comparing the new expression values to
these two averages, one comparison per gene in the signa-
ture. Moreover, these class averages cannot be computed
from the same training data from which the signature is
induced since the signature is derived from combining
multiple signatures derived from different data sets with
differing probe sets. Hence, the only choice for testing the
Rhodes signature is cross-validation on a test set, which
confers a considerable advantage due to the overall homo-
geneity of the profiles in each test set (e.g., removing any
normalization issues), resulting in an upward bias in the
classification rates.
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